Coherus Oncology, Inc.
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
CHRS$0.64-21.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Three Months Ended | ||||||
| · · March 31, | ||||||
| · · 2026 · · 2025 | ||||||
| Operating activities · · · · | ||||||
| Net loss | | $(38,327) | | $(56,569) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | ||
| Depreciation and amortization | | 881 | | 1,046 | ||
| Stock-based compensation expense | | 2,385 | | 5,372 | ||
| Loss on Sale Transactions, net (Note 6) | | | 388 | | | — |
| Change in fair value of derivatives | | | — | | | 12,608 |
| Other non-cash adjustments, net | | | 468 | | | 858 |
| Changes in operating assets and liabilities: | | | | | ||
| Trade receivables, net | | (4,282) | | 50,891 | ||
| Inventory | | | (11,312) | | | (22,244) |
| Prepaid manufacturing | | | 4,485 | | | 188 |
| Other prepaid, current and non-current assets | | | (3,071) | | | (5,334) |
| Accounts payable | | 2,564 | | 13,042 | ||
| Accrued rebates, fees and reserves | | (1,631) | | (17,129) | ||
| TSA related operating assets and liabilities, net | | (3,303) | | (1,836) | ||
| Accrued compensation | | 33 | | 1,606 | ||
| Accrued and other current and non-current liabilities | | (7,164) | | (8,325) | ||
| Net cash used in operating activities | | (57,886) | | (25,826) | ||
| | | | | | | |
| Investing activities | | | | | ||
| Purchases of investments in marketable securities | | (6,388) | | — | ||
| Proceeds from maturities of investments in marketable securities | | | 38,135 | | | — |
| Cash paid related to the Sale Transactions (Note 6) | | | — | | | (4,719) |
| Milestone payment to Junshi Biosciences | | | — | | | (12,500) |
| Other investing activities, net | | | (1,092) | | | (267) |
| Net cash provided by (used in) investing activities | | 30,655 | | (17,486) | ||
| | | | | | | |
| Financing activities | | | | | ||
| Proceeds from issuance of common stock under Public Offering, net of issuance costs | | | 53,650 | | | — |
| Taxes paid related to net share settlement | | (112) | | | (264) | |
| Other financing activities, net | | | 52 | | | — |
| Net cash provided by (used in) financing activities | | 53,590 | | (264) | ||
| | | | | | | |
| Net increase (decrease) in cash, cash equivalents and restricted cash | | 26,359 | | (43,576) | ||
| Cash, cash equivalents and restricted cash at beginning of period | | 89,119 | | 126,250 | ||
| Cash, cash equivalents and restricted cash at end of period | | $115,478 | | $82,674 | ||
| | | | | | | |
** Coherus Oncology, Inc.**
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.